S100A8 and myocardial infarction: Plasma levels of MRP‐8/14 heterodimer were higher in STEMI patients in compare with stable CAD. The risk of a first cardiovascular event increased with each increasing quartile of baseline MRP‐8/14 (range of follow‐up 0.01−5.9 years) (111 myocardial infarctions, 111 strokes, and 33 cardiovascular deaths). Risks were independent of standard risk factors and C‐reactive protein.